Background Image
Previous Page  166 / 182 Next Page
Show Menu
Previous Page 166 / 182 Next Page
Page Background





Mercadante S, Gatti A, Porzio G, Lo Presti C, Aielli F, Adile C, Casuccio A. Dosing fentanyl

buccal tablet for breakthrough cancer pain: dose titration versus proportional doses.

Curr Med Res Opin 2012; 28(6): 963-968.


Mercadante S, Intravaia G, Villari P, Ferrera P, Riina S, Mangione S. Intravenous morphi-

ne for episodic-breakthrough pain in an acute palliative care unit: a confirmatory study.

J Pain Symptom Manage 2008; 35: 307-313.


Mercadante S, Maddaloni S, Roccella S, Salvaggio L. Predictive factors in advanced

cancer pain treated only by analgesics. Pain 1992; 50: 151-155.


Mercadante S, Radbruch L, Caraceni A, Cherny N, Kaasa S, Nauck F, Ripamonti C, De

Conno F; Steering Committee of the European Association for Palliative Care (EAPC)

Research Network. Episodic (breakthrough) pain. Consensus conference of an Expert

Working Group of the European Association for Palliative Care. Cancer 2002; 94(3):



Mercadante S, Radbruch L, Davies A, Poulain P, Sitte T, Perkins P, Colberg T, Camba MA.

A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for

the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial.

Curr Med Res Opin 2009; 25(11): 2805-2815.


Mercadante S, Sapio M, Villari P. Suprascapular nerve block by catheter for breakt-

hrough shoulder cancer pain. Regional Anesthesia 1995; 20: 343-346.


Mercadante S, Villari P, Ferrera P, Bianchi M, Casuccio A. Safety and effectiveness of

intravenous morphine for episodic-breakthrough pain, using a fixed ratio with the oral

daily morphine dose. J Pain Symptom Manage 2004; 27: 352-359.


Mercadante S, Villari P, Ferrera P, Casuccio A, Mangione S, Intravaia G. Transmucosal

fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for

episodic-breakthrough pain. Br J Cancer 2007; 96: 1828-1833.


Mercadante S, Villari P, Ferrera P, Casuccio A. Optimization of opioid therapy for pre-

venting incident pain associated with bone metastases. Journal of Pain and Symptom

Management 2004; 28: 505-510.


Mercadante S, Villari P, Ferrera P, Mangione S, Casuccio A. The use of opioids for break-

through pain in acute palliative care unit by using doses proportional to opioid basal

regimen. Clin J Pain 2010; 26: 306-309.


Mercadante S. Breakthrough pain: on the road again. Eur J Pain 2009; 13: 329-430.


Mercadante S. Managing breakthrough pain. Curr Pain Headache Rep. 2011; 15(4):



Mercadante S. Oral trasmucosal fentanyl citrate for breakthrough pain treatment in

cancer patients. Expert Opin Pharmacother 2012; 13(6): 873-878.


Mercadante S. Pharmacotherapy for breakthrough cancer pain. Drugs 2012; 72(2):



Mercadante S. The use of rapid onset opioids for breakthrough cancer pain: the chal-

lenge of its dosing. Crit Rev Oncol Hematol. 2011; 80(3): 460-465.